NASDAQ$RLAY

Relay Therapeutics Inc. · Q2 2021 earnings

Q2 2021 earnings · · Investor relations

Headline financials

Total Revenue

$844K

No prior period
EPS (adj)

-$0.64

Previous: -$6.06+89.4%
Capital Expenditures

-$855K

No prior period
Free Cash Flow

-$194M

No prior period
Net Income

-$193M

Previous: -$26.7M-623.7%
Operating Income

-$194M

Previous: -$27.7M-598.4%
Gross Profit

$844K

Previous: -$21.7M+103.9%

Revenue & EPS history

Relay Therapeutics · Revenue · Quarterly

$844K

Q2 2021
Beat estimate in 7 of 14 quarters(50%)
ActualEstimate

Revenue by segment

Relay Therapeutics · $25.2M total across 1 segment · Q3 2023

  • License and Other Revenue
    $25.2M

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2021

Historical avgQ2 2021

+0.2%

Avg return

Earnings day

-0.4%

Avg return

5 days after

-0.5%

Avg return

30 days after

57%

13 / 23 earnings

Positive

+11.7%

Q4 2025

Best reaction

-19.5%

Q1 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.7%-2.5%+11.1%
Q4 2025+11.7%+10.8%+4.8%
Q3 2025-7.4%-5.5%+17.6%
Q1 2025-4.8%-9.6%-2.4%
Q4 2024-13.3%-14.9%-27.5%
Q3 2024+3.2%+3.5%-22.5%
Q2 2024-6.8%-5.6%-8.6%
Q1 2024+5.7%+1.2%-3.8%
Q4 2023-4.6%-1.8%-25.7%
Q3 2023+10.1%+19.3%+27.4%
Q2 2023+7.8%+3.5%-3.2%
Q1 2023+0.5%-5.3%+2.3%
Q4 2022-3.6%-8.8%-13.5%
Q3 2022-4.3%-6.8%-12.4%
Q2 2022+3.8%-1.6%+31.7%
Q1 2022-19.5%-33.5%-31.6%
Q4 2021+11.5%+17.4%+40.1%
Q3 2021+1.7%+0.6%-19.6%
Q2 2021+1.0%+0.2%-1.7%
Q1 2021+5.7%+8.5%+23.9%
Q4 2020-2.3%+2.0%-13.5%
Q3 2020+0.5%+13.5%+5.7%
Q2 2020+8.0%+5.3%+8.5%
Q1 2020
Q4 2019
Q3 2019
Q2 2019
Q1 2019

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro